ReviewInternational archives of allergy and immunology2020
Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020.
Review in International archives of allergy and immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 170 citations in OpenAlex.
- The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.Allergy · 2026Guideline
- Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First-in-human, randomized, ascending-dose studies.British journal of clinical pharmacology · 2025Trial
- Development and validation of a clinically applicable biomarker panel for identifying autoimmune type IIb chronic spontaneous urticaria.The World Allergy Organization journal · 2026Article
- Omalizumab Therapy Results in Defined Behavioural Changes and Improvements in Quality of Life in Solar Urticaria.Photodermatology, photoimmunology & photomedicine · 2026Article
- Nociceptive pain as a clinical presentation of chronic urticaria and disappearance with immunoglobulin/histamine complex therapy: a case report.Ewha medical journal · 2026Article
- Chronic spontaneous cholinergic urticaria: advances in immunological mechanisms focusing on neuro-immune crosstalk and novel targeted therapeutic strategies.Frontiers in immunology · 2026Review
- Model-Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria.CPT: pharmacometrics & systems pharmacology · 2025Article
- Can the Control of Chronic Spontaneous Urticaria Symptoms Depend on the Stress-Coping Styles?Diagnostics (Basel, Switzerland) · 2025Article
- Mast cell tryptase induces nuclear remodelling and reduced growth in breast cancer cells.Cell death discovery · 2025Article
- Biological and target synthetic treatments for chronic spontaneous urticaria: A systematic review and network meta-analysis.Clinical and translational allergy · 2025Article
- VITAMIN D IN PATIENTS WITH INFLAMMATORY SKIN DISEASES.Acta clinica Croatica · 2025Review
- A retrospective analysis of factors influencing response to omalizumab treatment in Indian patients with antihistamine refractory chronic spontaneous urticaria.Asia Pacific allergy · 2025Article
- Disease control and quality of life in chronic spontaneous urticaria and recurrent angioedema are strongly linked, but not in all patients.Clinical and translational allergy · 2025Article
- Assesment of Salivary and Serum Levels of HBD2 in Patients with Chronic Angioedema.Journal of clinical medicine · 2024Article
- Alarmins in Chronic Spontaneous Urticaria: Immunological Insights and Therapeutic Perspectives.Biomedicines · 2024Review
- Biomarkers for Short-Term Omalizumab Response in Chronic Spontaneous Urticaria.Annals of dermatology · 2024Article
- Global Burden of Vaccine-Associated Chronic Urticaria, 2010-2023: From the Global Pharmacovigilance Database.Allergy, asthma & immunology research · 2024Article
- Mast Cells are Dependent on Glucose Transporter 1 (GLUT1) and GLUT3 for IgE-mediated Activation.Inflammation · 2024Article
- Identification of key genes and molecular mechanisms of chronic urticaria based on bioinformatics.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- The Alarmin Triad-IL-25, IL-33, and TSLP-Serum Levels and Their Clinical Implications in Chronic Spontaneous Urticaria.International journal of molecular sciences · 2024Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 15 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This update on chronic urticaria (CU) focuses on the prevalence and pathogenesis of chronic spontaneous urticaria (CSU), the expanding spectrum of patient-reported outcome measures (PROMs) for assessing CU disease activity, impact, and control, as well as future treatment options for CU. This update is needed, as several recently reported findings have led to significant advances in these areas. Some of these key discoveries were first presented at past meetings of the Collegium Internationale Allergologicum (CIA). New evidence shows that the prevalence of CSU is geographically heterogeneous, high in all age groups, and increasing. Several recent reports have helped to better characterize two endotypes of CSU: type I autoimmune (or autoallergic) CSU, driven by IgE to autoallergens, and type IIb autoimmune CSU, which is due to mast cell (MC)-targeted autoantibodies. The aim of treatment in CU is complete disease control with absence of signs and symptoms as well as normalization of quality of life (QoL). This is best monitored by the use of an expanding set of PROMs, to which the Angioedema Control Test, the Cholinergic Urticaria Quality of Life Questionnaire, and the Cholinergic Urticaria Activity Score have recently been added. Current treatment approaches for CU under development include drugs that inhibit the effects of signals that drive MC activation and accumulation, drugs that inhibit intracellular pathways of MC activation and degranulation, and drugs that silence MCs by binding to inhibitory receptors. The understanding, knowledge, and management of CU are rapidly increasing. The aim of this review is to provide physicians who treat CU patients with an update on where we stand and where we will go. Many questions and unmet needs remain to be addressed, such as the development of routine diagnostic tests for type I and type IIb autoimmune CSU, the global dissemination and consistent use of PROMs to assess disease activity, impact, and control, and the development of more effective and well-tolerated long-term treatments for all forms of CU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.